Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3) - 14/12/17
This work was supported by Valeant Pharmaceuticals North America LLC, Bridgewater, New Jersey. |
|
Conflicts of interest: Dr Blauvelt has served as a scientific adviser and clinical study investigator for AbbVie, Inc, Amgen, Inc, Boehringer Ingelheim, Celgene Corporation, Dermira, Inc, Genentech, Inc, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly & Co, Merck & Co, Inc, Novartis AG, Pfizer, Inc, Regeneron Pharmaceuticals, Inc, Sandoz, Sanofi Genzyme, Sun Pharmaceutical Industries, Ltd, UCB, and Valeant Pharmaceuticals North America LLC, and, as a paid speaker for Eli Lilly & Co, Regeneron Pharmaceuticals, Inc, and Sanofi Genzyme, Dr Papp is a consultant, an investigator, and on the speakers bureau for AbbVie, Amgen, Astellas, Bayer, Boehringer Ingelheim, Celgene, Eli Lilly, Forward, Galderma, Janssen, LEO, Merck, Novartis, Pfizer, Roche, and UCB. Dr Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from Amgen, Anacor, Aqua, Canfite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Eli Lilly, Ferndale, Janssen, Leo, Merck, Novartis, Pfizer, Sandoz, and Valeant. Dr Green is an investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Merck, Novartis, and Valeant. Dr Hsu is a consultant for AbbVie, Amgen, Novartis, Eli Lilly, Janssen, Regeneron, Sanofi, and Valeant. Drs Bhatt, Rastogi, Pillai, and Israel are employees of Valeant Pharmaceuticals. |
Vol 77 - N° 2
P. 372-374 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?